The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (ARI‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell non‐Hodgkin lymphoma
Open Access
- 31 October 2023
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 204 (2) , 525-533
Abstract
Summary: Varnimcabtagene autoleucel (var‐cel) is an academic anti‐CD19 chimeric antigen receptor (CAR) product used for the treatment of non‐Hodgkin lymphoma (NHL) in the CART19‐BE‐01 trial. Here we report updated outcomes of patients with NHL treated with var‐cel. B‐cell recovery was compared with patients with acute lymphoblastic leukaemia (ALL). Forty‐five patients with NHL were treated. Cytokine release syndrome (any grade) occurred in 84% of patients (4% grade ≥3) and neurotoxicity in 7% (2% grade ≥3). The objective response rate was 73% at Day +100, and the 3‐year duration of response was 56%. The 3‐year progression‐free and overall survival were 40% and 52% respectively. High lactate dehydrogenase was the only covariate with an impact on progression‐free survival. The 3‐year incidence of B‐cell recovery was lower in patients with NHL compared to ALL (25% vs. 60%). In conclusion, in patients with NHL, the toxicity of var‐cel was manageable, while B‐cell recovery was significantly prolonged compared to ALL. This trial was registered as NCT03144583.Keywords
Funding Information
- Instituto de Salud Carlos III (PI13/676, PI18/775, PICI14/122, PIE13/33)
- Generalitat de Catalunya (PERIS IPFE SLT006/17/301)
This publication has 25 references indexed in Scilit:
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumJournal of Clinical Oncology, 2020
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2020
- Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical TrialFrontiers in Immunology, 2020
- High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapyBlood, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic InstitutionsMolecular Therapy - Methods & Clinical Development, 2019
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasNew England Journal of Medicine, 2017
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Acute Lymphoblastic Leukemia, Version 2.2015Journal of the National Comprehensive Cancer Network, 2015